MARKET

AEMD

AEMD

Aethlon Medical
NASDAQ
0.8732
-0.0179
-2.01%
After Hours: 0.9600 +0.0868 +9.94% 19:53 06/26 EDT
OPEN
0.8900
PREV CLOSE
0.8911
HIGH
0.9781
LOW
0.8346
VOLUME
276.07K
TURNOVER
--
52 WEEK HIGH
27.40
52 WEEK LOW
0.8346
MARKET CAP
2.07M
P/E (TTM)
-0.0823
1D
5D
1M
3M
1Y
5Y
1D
Aethlon Medical announces publication demonstrating potential of Hemopurifier
TipRanks · 2d ago
Aethlon Medical Publishes Peer-Reviewed Research Demonstrating Novel Long COVID Biomarker And Potential Therapeutic Target For Hemopurifier In International Journal of Molecular Sciences
Benzinga · 2d ago
Aethlon Medical study flags Long COVID biomarker, supports Hemopurifier evaluation
PUBT · 2d ago
Aethlon Medical Announces Publication Demonstrating Novel Long COVID Biomarker and Potential Therapeutic Target for the Hemopurifier®
PR Newswire · 2d ago
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 6d ago
*Aethlon Medical Files to Offer Up to 6M Shrs and 6M Accompanying Warrants
Dow Jones · 6d ago
Aethlon Medical files to sell 6M shares of common stock, warrants
TipRanks · 6d ago
Weekly Report: what happened at AEMD last week (0615-0619)?
Weekly Report · 6d ago
More
About AEMD
Aethlon Medical, Inc. is a clinical-stage medical device company. The Company is focused on advancing the Hemopurifier (HP), a clinical-stage immunotherapeutic device intended for applications in cancer, life-threatening viral infections, and organ transplantation and other areas of significant unmet needs. In pre-clinical studies, the Hemopurifier has exhibited the capacity to remove harmful extracellular vesicles (EVs) and enveloped viruses from biological fluids, utilizing its proprietary lectin-based mechanism. These extracellular vesicles have been implicated in disease processes such as immune suppression and metastasis in cancer as well as in the progression of severe life-threatening infectious diseases. The United States Food and Drug Administration (FDA) has designated the Hemopurifier as a Breakthrough Device for the treatment of individuals with advanced or metastatic cancer who are unresponsive to or intolerant of standard of care therapy.

Webull offers Aethlon Medical Inc stock information, including NASDAQ: AEMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AEMD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AEMD stock methods without spending real money on the virtual paper trading platform.